ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Bupivacaine

Also written as “HTX-011”, “SKY0402” and “Bupivacaine HCl”.

Its studies are mostly in Pain, Postoperative · Pain · Hernia, Inguinal · Bunion · Hemorrhoids, led by 10 companies.

Drug pageBupivacaine: every studyMany companies study it; this page follows only the 56 they lead. All 1,200 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Oct 24, 201156 company-led studies, 4 open or runningNext primary completion: Nov 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pacira BioSciencesits history only230 open or runningphase 4since Oct 24, 2011Jun 11, 2007none ahead
Heron Therapeutics171 open or runningphase 4since Oct 10, 2018Jun 9, 2015none ahead
Innocollits history only60 open or runningphase 3since Aug 12, 2015Oct 18, 2010none ahead
Bausch Health Companiesits history only20 open or runningphase 3since Oct 9, 2015Mar 30, 2010none ahead
Cristália Produtos Químicos Farmacêuticos Ltda.its history only20 open or runningphase 3since Feb 23, 2011Feb 23, 2011none ahead
Jiangsu HengRui Medicineits history only22 open or runningphase 4since Mar 13, 2024Mar 13, 2024Nov 2026phase 2 · NCT06529432
Ascension Healthits history only10 open or runningphase 3since Nov 20, 2019Nov 20, 2019none ahead
Liquidia Technologiesits history only10 open or runningphase 1since Nov 22, 2016Nov 22, 2016none ahead
Rebel Medicineits history only11 open or runningphase 2since Apr 28, 2026Apr 28, 2026none ahead
Tian Medicalits history only10 open or runningphase 4since Oct 16, 2012Oct 16, 2012none ahead

Also a collaborator on its studies: Pfizer, Premier Research Group and Richmond Pharmacology.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Heron Therapeutics only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 9, 2015First study: phase 2 study in AgnosiaFirst studyNCT02471898 · 71 enrolled · United States
  2. Jul 16, 2015Phase 2 study in Pain, PostoperativeNCT02504580 · 463 enrolled · United States
  3. Jan 3, 20172 phase 2 studies in Pain, PostoperativeNCT03011333, NCT03015532
  4. Jul 31, 2017Phase 3 study in Pain, PostoperativeNCT03237481 · 418 enrolled · United States, Belgium
  5. Sep 25, 2017Phase 3 study in Pain, PostoperativeNCT03295721 · 412 enrolled · United States
  6. Oct 1, 20182 phase 2 studies in Pain, PostoperativeNCT03695367, NCT03718039
  7. Oct 10, 2018Phase 4 study in Pain, PostoperativeNCT03705065 · 30 enrolled · United States
  8. Apr 5, 2019Phase 3 study in AgnosiaNCT03907176 · 209 enrolled · United States
  9. Apr 17, 2019Phase 2 study in AgnosiaNCT03922048
  10. May 9, 2019Phase 2 study in Pain, PostoperativeNCT03955211 · 25 enrolled · United States
  11. Jun 3, 2019Phase 3 study in AgnosiaNCT03974932 · 116 enrolled · United States
  12. May 27, 2021Phase 2 study in Pain, PostoperativeNCT04911062 · 32 enrolled · United States
  13. Oct 1, 2021Phase 4 study in AgnosiaNCT05109312 · 90 enrolled · United States
  14. Oct 25, 20232 phase 4 studies in Pain, PostoperativeNCT06109428, NCT06109415

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 17 Heron Therapeutics leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06109428Pain, Postoperative · United States4CompletedMar 29, 202237
NCT06109415Pain, Postoperative · United States4CompletedJul 18, 202230
NCT05109312Agnosia · United States4Active, not recruitingJun 202490
NCT04911062Pain, Postoperative · United States2CompletedJul 29, 202232
NCT03974932Agnosia · United States3CompletedDec 7, 2020116
NCT03955211Pain, Postoperative · United States2CompletedDec 3, 202125
NCT03922048Agnosia2WithdrawnNov 20250
NCT03907176Agnosia · United States3CompletedOct 25, 2021209
NCT03718039Pain, Postoperative · United States2CompletedJan 31, 201978
NCT03705065Pain, Postoperative · United States4CompletedOct 8, 201830
NCT03695367Pain, Postoperative · United States2CompletedNov 20, 201863
NCT03295721Pain, Postoperative · United States3CompletedJan 8, 2018412
NCT03237481Pain, Postoperative · United States, Belgium3CompletedDec 22, 2017418
NCT03015532Pain, Postoperative · United States2CompletedApr 20, 2018285
NCT03011333Pain, Postoperative · United States2CompletedFeb 1, 2018243
NCT02504580Pain, Postoperative · United States2CompletedMar 2017463
NCT02471898Agnosia · United States2CompletedSep 201571

How it is read

Names in the registry

  • “HTX-011”, 20 entries
  • “SKY0402”, 12 entries
  • “Bupivacaine HCl”, 7 entries
  • “Bupivacaine”, 5 entries
  • “Bupivacaine Liposome Injection”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.